top of page

Harnessing seaweed extract to treat ischemic stroke



World Thrombosis Day is this week and the good news is, despite pandemic restrictions, researchers have been working hard in their labs around the world to develop new innovative solutions to treat thrombosis-related conditions.


Currently for ischemic stroke, a stroke caused by a blood clot, the main treatment is an intravenous injection of recombinant tissue Plasminogen Activators (rtPA) which breaks up the clot. Studies show that patients who receive rtPA within 3-4.5hrs have better and more complete recoveries, [1]. Due to the limitations of this narrow therapeutic window and because the rate of acute recanalization (i.e. reestablishment of blood flow) is low; only 30% of patients experience full or partial recanalization [2]; it is necessary to investigate other strategies and treatment options.


On this World Thrombosis Day and in advance of World Stroke Day, taking place on 29th October, we’d like to shine a light on a paper recently published in Biomaterials that includes work from one of our customers, [3].


Study Overview

Researchers at the Université de Paris (UMR S1148, INSERM) successfully designed and fabricated fucoidan-functionalized 100% polysaccharide submicroparticles (Fuco-SPs) from biocompatible and FDA approved components as a P-selectin targeting drug delivery system for thrombolytic therapy. This mechanism is illustrated below from previous work by some of the same researchers, [4].

Graphical abstract from Maya Juenet et al. Thrombolytic therapy based on fucoidan-functionalized polymer nanoparticles targeting P-selectin, Biomaterials, Volume 156, 2018, Pages 204-216, ISSN 0142-9612, https://doi.org/10.1016/j.biom